RecruitingNot Applicable

Tessa Jowell BRAIN MATRIX - Platform Study

United Kingdom1,000 participantsStarted 2020-11-24

Plain-language summary

The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis). * Valid written informed consent for the study. Exclusion Criteria: * Primary spinal cord tumours * Active treatment of other malignancy * Contraindication to MRI * Patients without standard of care imaging available

What they're measuring

Time (from biopsy) to integrated histological-molecular diagnosis using standard-of-care NHS practice

Timeframe: 28 days

Time (from biopsy) to WGS report to the treating clinician using NHS Genomic Medicine Service

Timeframe: 28

Trial details

NCT IDNCT04274283

SponsorUniversity of Birmingham

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-02

Contact for this trial

Rhys Mant

0121 414 6788 brainmatrix@trials.bham.ac.uk

View on ClinicalTrials.gov More Glioma trials